NASDAQ:ANAB AnaptysBio Q1 2025 Earnings Report $53.87 -1.29 (-2.34%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$53.66 -0.21 (-0.39%) As of 09/11/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast AnaptysBio EPS ResultsActual EPS-$1.28Consensus EPS -$1.30Beat/MissBeat by +$0.02One Year Ago EPSN/AAnaptysBio Revenue ResultsActual Revenue$27.77 millionExpected Revenue$15.27 millionBeat/MissBeat by +$12.50 millionYoY Revenue GrowthN/AAnaptysBio Announcement DetailsQuarterQ1 2025Date5/5/2025TimeBefore Market OpensConference Call DateMonday, May 5, 2025Conference Call Time12:00AM ETUpcoming EarningsAnaptysBio's Q2 2026 earnings is estimated for Wednesday, September 16, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, September 17, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) AnaptysBio Earnings HeadlinesAlphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)September 9 at 11:51 AM | insidermonkey.comAnaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 1, 2026 | globenewswire.comGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet production stayed at 5.9 million ounces, unchanged from 2020. Newmont, Barrick and Agnico all face the same reserve shortage, pushing majors toward acquiring smaller producing miners. Recent deals show the pattern: Rupert Resources jumped 67 percent and G2 Goldfields jumped 79 percent the day their buyouts were announced. Analyst Garrett Goggin has identified four junior miners he believes are next on the shopping list.September 12 at 1:00 AM | Golden Portfolio (Ad)GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug ControlAugust 17, 2026 | finance.yahoo.comAnaptysBio, Inc.August 12, 2026 | edition.cnn.comAnaptysBio Shareholders Back Board, Governance and IncentivesAugust 11, 2026 | tipranks.comSee More AnaptysBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AnaptysBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AnaptysBio and other key companies, straight to your email. Email Address About AnaptysBioAnaptysBio (NASDAQ:ANAB) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines for cancer and immune-mediated diseases. The company’s programs are designed to modulate immune-cell signaling and address conditions in which the immune system is either insufficiently active, as in cancer, or overly active, as in autoimmune and inflammatory disorders. AnaptysBio’s pipeline has included rosnilimab, an investigational antibody targeting CD200R1, and other immune-cell modulators aimed at autoimmune and inflammatory diseases. The company uses its proprietary antibody discovery and engineering capabilities to develop therapeutic candidates, with programs advancing through clinical development and partnerships. Its research has historically included immuno-oncology programs as well as treatments for diseases such as rheumatoid arthritis and inflammatory bowel disease. Founded in 2005 and headquartered in San Diego, California, AnaptysBio has also generated value through licensing and collaboration agreements. Its antibody-discovery platform contributed to dostarlimab, an anti-PD-1 therapy developed by Tesaro and now marketed by GSK as Jemperli for certain cancer indications. The company’s operations and clinical development activities are primarily centered in the United States, with studies and commercial partnerships extending internationally. AnaptysBio is led by Chief Executive Officer Hamza Suria.View AnaptysBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/07 - 09/11Kroger’s Textbook Entry for Buy-and-Hold InvestorsOracle’s AI Spending Is Still Huge, But the Payoff Is Starting to Show in EarningsAmgen Drops 10% on a Trial It Didn't Even RunOil Above $100 Is Creating a New Opportunity Beyond the Major ProducersAST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing WindowAmerican Eagle Goes on Sale: Is It Time to Buy? Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
